Select Publications
Book Chapters
2011, 'Spinal Muscular Atrophy', in Encyclopedia of Life Sciences (eLS), John Wiley & Sons, Ltd., Chichester, pp. 1 - 7, http://dx.doi.org/10.1002/9780470015902.a0006011.pub2
,Journal articles
2024, 'A contemporary analysis of the Australian clinical and genetic landscape of spinal muscular atrophy: a registry based study', The Lancet Regional Health - Western Pacific, 53, http://dx.doi.org/10.1016/j.lanwpc.2024.101237
,2024, 'Outcomes of early-treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study', Muscle and Nerve, 70, pp. 1247 - 1256, http://dx.doi.org/10.1002/mus.28267
,2024, 'Codesign and evaluation of advanced therapeutic information resources for and with families of children with neurological conditions: a mixed methods cross-sectional study.', Arch Dis Child, http://dx.doi.org/10.1136/archdischild-2024-327914
,2024, 'Clinician Perceptions of Family-Centered Care in Pediatric and Congenital Heart Settings', JAMA network open, 7, pp. e2422104, http://dx.doi.org/10.1001/jamanetworkopen.2024.22104
,2024, '‘High hopes for treatment’: Australian stakeholder perspectives of the clinical translation of advanced neurotherapeutics for rare neurological diseases', Health Expectations, 27, http://dx.doi.org/10.1111/hex.14063
,2024, 'RAINBOWFISH: Primary Efficacy and Safety Data in Risdiplam-treated Infants with Presymptomatic Spinal Muscular Atrophy (SMA) (S37.006)', Neurology, 102, http://dx.doi.org/10.1212/wnl.0000000000205694
,2024, 'Exploring caregivers' attitudes and beliefs about nutrition and weight management for young people with Duchenne muscular dystrophy', Muscle and Nerve, 69, pp. 448 - 458, http://dx.doi.org/10.1002/mus.28062
,2024, 'Newborn screening for Duchenne muscular dystrophy: the perspectives of stakeholders', The Lancet Regional Health - Western Pacific, 45, http://dx.doi.org/10.1016/j.lanwpc.2024.101049
,2024, '‘Integrating Ethics and Equity with Economics and Effectiveness for newborn screening in the genomic age: A qualitative study protocol of stakeholder perspectives', PLoS ONE, 19, pp. 1 - 13, http://dx.doi.org/10.1371/journal.pone.0299336
,2024, 'Deciphering spinal muscular atrophy: the need for more research', The Lancet Neurology, 23, pp. 134 - 136, http://dx.doi.org/10.1016/S1474-4422(23)00502-1
,2024, 'Life-Saving Treatments for Spinal Muscular Atrophy Global Access and Availability', Neurology: Clinical Practice, 14, http://dx.doi.org/10.1212/CPJ.0000000000200224
,2024, 'Clinician Understanding, Acceptance and utilization of Ketogenic diet therapy for epilepsy in Australia and New Zealand: An online survey', Epilepsy and Behavior Reports, 28, http://dx.doi.org/10.1016/j.ebr.2024.100711
,2024, 'Getting Wheels: development and evaluation of a psychoeducational resource for parents of children with a neuromuscular condition following recommendation of wheelchair equipment', Disability and Rehabilitation: Assistive Technology, 19, pp. 2630 - 2640, http://dx.doi.org/10.1080/17483107.2024.2310282
,2024, 'The emerging spectrum of neurodevelopmental comorbidities in early-onset Spinal Muscular Atrophy', European Journal of Paediatric Neurology, 48, pp. 67 - 68, http://dx.doi.org/10.1016/j.ejpn.2023.11.006
,2024, '179P Intravenous and intrathecal onasemnogene abeparvovec gene therapy in symptomatic and presymptomatic SMA: long-term follow-up study', Neuromuscular Disorders, 43, pp. 104441.614 - 104441.614, http://dx.doi.org/10.1016/j.nmd.2024.07.623
,2024, '21O RAINBOWFISH: 2-year efficacy and safety data of risdiplam in infants with presymptomatic SMA', Neuromuscular Disorders, 43, pp. 104441.738 - 104441.738, http://dx.doi.org/10.1016/j.nmd.2024.07.747
,2023, 'Characterizing Common Phenotypes Across the Childhood Dementia Disorders: A Cross-sectional Study From Two Australian Centers', Pediatric Neurology, 149, pp. 75 - 83, http://dx.doi.org/10.1016/j.pediatrneurol.2023.09.006
,2023, 'Gene therapy-based strategies for spinal muscular atrophy—an Asia-Pacific perspective', Molecular and Cellular Pediatrics, 10, http://dx.doi.org/10.1186/s40348-023-00171-5
,2023, 'The psychosocial impact of childhood dementia on children and their parents: a systematic review', Orphanet Journal of Rare Diseases, 18, http://dx.doi.org/10.1186/s13023-023-02859-3
,2023, 'Emerging role for sphingolipids in the genetics of amyotrophic lateral sclerosis', Journal of Neurology, Neurosurgery and Psychiatry, 95, pp. 101 - 102, http://dx.doi.org/10.1136/jnnp-2023-332719
,2023, 'The Australian landscape of newborn screening in the genomics era', Rare Disease and Orphan Drugs Journal, 2, http://dx.doi.org/10.20517/rdodj.2023.30
,2023, 'Safety and Efficacy of Intravenous Onasemnogene Abeparvovec in Patients with Spinal Muscular Atrophy: Interim Findings from the Phase 3 SMART Study', Neuropediatrics, 54, pp. s1 - s32, http://dx.doi.org/10.1055/s-0043-1777167
,2023, 'The collective burden of childhood dementia: a scoping review', Brain, 146, pp. 4446 - 4455, http://dx.doi.org/10.1093/brain/awad242
,2023, 'Prospective assessment of vincristine-induced peripheral neuropathy in paediatric acute lymphoblastic leukemia', Clinical Neurophysiology, 154, pp. 157 - 168, http://dx.doi.org/10.1016/j.clinph.2023.08.002
,2023, 'Presymptomatic spinal muscular atrophy: a cautionary approach to the proposed new terminology', Brain, 146, pp. E65 - E66, http://dx.doi.org/10.1093/brain/awad061
,2023, 'Oculomotor Apraxia as an Early Presenting Sign of Juvenile-Onset Huntington's Disease', Movement Disorders Clinical Practice, 10, pp. S12 - S14, http://dx.doi.org/10.1002/mdc3.13775
,2023, 'Treatment of severe acute necrotizing encephalopathy of childhood with interleukin-6 receptor blockade in the first 24 h as add-on immunotherapy shows favorable long-term outcome at 2 years', Brain and Development, 45, pp. 401 - 407, http://dx.doi.org/10.1016/j.braindev.2023.03.002
,2023, 'Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy', Molecular Therapy, 31, pp. 1979 - 1993, http://dx.doi.org/10.1016/j.ymthe.2023.03.032
,2023, 'The Carrier Frequency of Two SMN1 Genes in Parents of Symptomatic Children with SMA and the Significance of SMN1 Exon 8 in Carriers', Genes, 14, http://dx.doi.org/10.3390/genes14071403
,2023, 'CSF neopterin, quinolinic acid and kynurenine/tryptophan ratio are biomarkers of active neuroinflammation', eBioMedicine, 91, http://dx.doi.org/10.1016/j.ebiom.2023.104589
,2023, '“The usual challenges of work are all magnified”: Australian paediatric health professionals’ experiences during the COVID-19 pandemic', International Journal of Cardiology Congenital Heart Disease, 11, http://dx.doi.org/10.1016/j.ijcchd.2022.100434
,2023, 'Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study', The Lancet Child and Adolescent Health, 7, pp. 159 - 170, http://dx.doi.org/10.1016/S2352-4642(22)00342-X
,2023, 'Childhood Dementia: A Collective Clinical Approach to Advance Therapeutic Development and Care', Pediatric Neurology, 139, pp. 76 - 85, http://dx.doi.org/10.1016/j.pediatrneurol.2022.11.015
,2023, 'Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective', Expert Review of Neurotherapeutics, 23, pp. 571 - 586, http://dx.doi.org/10.1080/14737175.2023.2218549
,2023, 'Identification of Novel CSF-Derived miRNAs in Treated Paediatric Onset Spinal Muscular Atrophy: An Exploratory Study', Pharmaceutics, 15, http://dx.doi.org/10.3390/pharmaceutics15010170
,2023, 'Multidisciplinary perspectives and practices of wheelchair prescription for children with neuromuscular conditions', Disability and Rehabilitation: Assistive Technology, 18, pp. 166 - 174, http://dx.doi.org/10.1080/17483107.2020.1839793
,2023, 'Newborn Screening for the Diagnosis and Treatment of Duchenne Muscular Dystrophy', Journal of Neuromuscular Diseases, 10, pp. 15 - 28, http://dx.doi.org/10.3233/JND-221535
,2023, 'Rare diseases: New approaches to diagnosis and care', Medicine Today, 24, pp. 69 - 76
,2023, 'Childhood dementia: the collective impact and opportunities for intervention', Alzheimer's & Dementia, 19, http://dx.doi.org/10.1002/alz.082583
,2023, 'Diagnosis and management of children with McArdle Syndrome (GSD V) in New South Wales.', JIMD Rep, 64, pp. 327 - 336, http://dx.doi.org/10.1002/jmd2.12389
,2023, 'O20 Safety and efficacy of intravenous onasemnogene abeparvovec in patients with spinal muscular atrophy: interim findings from the phase 3 SMART study', Neuromuscular Disorders, 33, pp. S191 - S191, http://dx.doi.org/10.1016/j.nmd.2023.07.489
,2023, 'P212 RAINBOWFISH: Primary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA)', Neuromuscular Disorders, 33, pp. S87 - S88, http://dx.doi.org/10.1016/j.nmd.2023.07.094
,2023, 'P230 Safety update: Risdiplam clinical trial program for spinal muscular atrophy (SMA)', Neuromuscular Disorders, 33, pp. S92 - S93, http://dx.doi.org/10.1016/j.nmd.2023.07.112
,2023, 'Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience.', Neuromuscul Disord, 33, pp. 531 - 538, http://dx.doi.org/10.1016/j.nmd.2023.04.007
,2022, '‘Advocacy groups are the connectors’: Experiences and contributions of rare disease patient organization leaders in advanced neurotherapeutics', Health Expectations, 25, pp. 3175 - 3191, http://dx.doi.org/10.1111/hex.13625
,2022, 'Incidence of Duchenne muscular dystrophy in the modern era; an Australian study', European Journal of Human Genetics, 30, pp. 1398 - 1404, http://dx.doi.org/10.1038/s41431-022-01138-2
,2022, 'The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: a narrative review', Orphanet Journal of Rare Diseases, 17, http://dx.doi.org/10.1186/s13023-022-02317-6
,2022, 'Circulating neurofilaments to track dorsal root ganglion toxicity risks with AAV-mediated gene therapy', Molecular Therapy - Methods and Clinical Development, 26, pp. 96 - 97, http://dx.doi.org/10.1016/j.omtm.2022.06.005
,2022, 'Delivering paediatric precision medicine: Genomic and environmental considerations along the causal pathway of childhood neurodevelopmental disorders', Developmental Medicine and Child Neurology, 64, pp. 1077 - 1084, http://dx.doi.org/10.1111/dmcn.15289
,